{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T08:58:07Z","timestamp":1767085087785},"reference-count":13,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2019,1,30]],"date-time":"2019-01-30T00:00:00Z","timestamp":1548806400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinics and Practice"],"abstract":"<jats:p>Direct oral anticoagulants have become increasingly used for atrial fibrillation and venothromboembolic disease. Thus far, there have been a few published cases of pericardial effusion associated with rivaroxban. However, there has been little published regarding the effects of concurrent medications and their effect on the cytochrome enzyme systems involved in rivaroxaban metabolism. We present a case of a 76-year-old female who develops a spontaneous haemopericardium after initiating rivaroxaban. After thorough medical reconciliation, we offer pharmacokinetic mechanisms that may have contributed to the haemopericardium. This case demonstrates the importance of reviewing patients medication lists and utilizing basic pharmacokinetics to prevent adverse events.<\/jats:p>","DOI":"10.4081\/cp.2019.1096","type":"journal-article","created":{"date-parts":[[2019,1,30]],"date-time":"2019-01-30T19:26:36Z","timestamp":1548876396000},"page":"1096","source":"Crossref","is-referenced-by-count":8,"title":["Isolated Hemopericardium after Initiation of Rivaroxaban: Implications and Potential Mechanisms"],"prefix":"10.3390","volume":"9","author":[{"given":"Adwait","family":"Mehta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Burkland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nilesh","family":"Mathuria","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2019,1,30]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Manesh","year":"2011","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1161\/CIRCULATIONAHA.111.055079","article-title":"Net clinical benefit of warfarin in patients with atrial fibrillation: a report from the Swedish atrial fibrillation cohort study","volume":"125","author":"Friberg","year":"2012","journal-title":"Circulation"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1093\/eurheartj\/ehu083","article-title":"Management of major bleeding events in patients treated with rivaroxaban vs. warfarin: results from the ROCKET AF trial","volume":"35","author":"Piccini","year":"2014","journal-title":"Eur Heart J"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.ijcard.2014.12.062","article-title":"Pericardial bleeding risk with nonvitamin K oral anticoagulants: a metaanalysis","volume":"182","author":"Caldeira","year":"2015","journal-title":"Int J Cardiol"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"e169","DOI":"10.1002\/phar.1474","article-title":"Isolated hemopericardium associated with rivaroxaban: first case report","volume":"34","author":"Shivamurthy","year":"2014","journal-title":"Pharmacotherapy"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"e75","DOI":"10.1016\/j.ijcard.2014.04.151","article-title":"Life-threatening haemorrhagic pericarditis associated with rivaroxaban","volume":"174","author":"Xu","year":"2014","journal-title":"Int J Cardiol"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1345\/aph.1R112","article-title":"Hemopericardium and cardiac tamponade associated with Dabigatran use","volume":"46","author":"DY","year":"2012","journal-title":"Ann Pharmacother"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40262-013-0100-7","article-title":"Clinical pharmacokinetic and pharmacodynamic profile of Rivaroxaban","volume":"53","author":"Mueck","year":"2014","journal-title":"Clin Pharmacokinet"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1477-9560-11-10","article-title":"Rivaroxaban and other novel oral anticoagulants pharmacokinetics in health subjects, specific patient populations and relevance of coagulation monitoring","volume":"11","author":"Mueck","year":"2013","journal-title":"Thromb J"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1111\/bcpt.12999","article-title":"Inhibition of in vitro metabolism of opioids by skeletal muscle relaxants","volume":"123","author":"Moody","year":"2018","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"624","DOI":"10.4103\/0253-7613.100395","article-title":"Effects of pravastatin on the pharmacokinetic parameters of nimodipine after oral and intravenous administration in rats: possible role of CYP3A4 inhibition by pravastatin","volume":"44","author":"Lee","year":"2012","journal-title":"Indian J Pharmacol"},{"key":"ref12","first-page":"201","article-title":"Competitive inhibitors of enzymes and their therapeutic application","volume":"9","author":"Bjelakovic","year":"2002","journal-title":"Med Biol"},{"key":"ref13","first-page":"391","article-title":"The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects","volume":"76","author":"Lynch","year":"2007","journal-title":"Am Fam Physician"}],"container-title":["Clinics and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.clinicsandpractice.org\/index.php\/cp\/article\/download\/1096\/949","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.clinicsandpractice.org\/index.php\/cp\/article\/download\/1096\/962","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.mdpi.com\/2039-7283\/9\/1\/1096\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,10]],"date-time":"2022-02-10T06:55:55Z","timestamp":1644476155000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2039-7283\/9\/1\/1096"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,30]]},"references-count":13,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,1]]}},"alternative-id":["cp.2019.1096"],"URL":"https:\/\/doi.org\/10.4081\/cp.2019.1096","relation":{},"ISSN":["2039-7283"],"issn-type":[{"value":"2039-7283","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,30]]}}}